Pembrolizumab: all 1,753 studies that test it
Page 4 of 18. Open to participants first (418), then studies with results posted, then the rest; newest registration first within each.
- A Substudy of Investigational Agents in Programmed Cell Death-1/Ligand 1 (PD-1/L1) Refractory Locally Advanced or Metastatic Urothelial Carcinoma (mUC) (MK-3475-04A)RecruitingNCT05562830Phase 1/2
- Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)RecruitingNCT05549297Phase 3
- Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung CancerRecruitingNCT05501665Phase 1/2
- Neoadjuvant PD-1 Blockade in Resectable Merkel Cell CarcinomaRecruitingNCT05496036Phase 2
- Low-Dose Interleukin-2 and Pembrolizumab for the Treatment of Stage IV Non-Small Cell Lung CancerRecruitingNCT05493566Early Phase 1
- START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of CancerRecruitingNCT05492682Phase 1
- Reinvigorating TNBC Response to Immunotherapy With Combination Myeloid Inhibition and RadiationRecruitingNCT05491226Phase 2
- Pembrolizumab and ADG106 in Advanced Solid Cancers and Triple Negative Breast CancerRecruitingNCT05491083Phase 1/2
- Novel Neoadjuvant and Adjuvant Strategy for Germline BRCA 1/2 Mutated Triple Negative Breast CancerRecruitingNCT05485766Phase 2
- Modulation of the Gut Microbiome With Pembrolizumab Following Chemotherapy in Resectable Pancreatic CancerRecruitingNCT05462496Phase 2
- MNK Inhibitor AUM001 in Combination With Either Pembrolizumab or Irinotecan to Treat Metastatic Colorectal CancerRecruitingNCT05462236Phase 2
- Anti-PD-1 Antibody Combined With Autologous DC and NK Cells in the Treatment of Digestive CarcinomaNot yet recruitingNCT05461235Phase 2
- Pembrolizumab in Combination With Low-dose PFas Neoadjuvant Treatment for Locally Advanced HNSCCRecruitingNCT05446467Phase 2
- Liver SBRT in Combination With Immune Checkpoint Inhibition in Patients With Metastatic Non-small Cell Lung CancerRecruitingNCT05430009Phase 1
- Highly Selective CDK7 Inhibitor Q901 in Selected Advanced Solid TumorsRecruitingNCT05394103Phase 1/2
- ERC1671 to Treat Malignant Gliomas When Given in Combination With GM-CSF, Cyclophosphamide, Bevacizumab and PembrolizumabNot yet recruitingNCT05366062Phase 2
- A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic CancerRecruitingNCT05365581Phase 1
- To Access the Safety and Effects of Intravenous Administration of VIR-5818 Alone and in Combination With Pembrolizumab in Adult Participants With Locally Advanced or Metastatic HER2-Expressing CancersRecruitingNCT05356741Phase 1/2
- A Phase II Study of the Combination of Azacitidine and Pembrolizumab for Patients Relapsed/Refractory Hodgkin's LymphomaRecruitingNCT05355051Phase 2
- Study of PAT in Patients With Solid Tumor CancersRecruitingNCT05338658Phase 1
- Pembrolizumab and Disitamab Vedotin in HER2-expressing Metastatic Colorectal CancerNot yet recruitingNCT05333809Phase 2
- A Study in Patients With Advanced CancersRecruitingNCT05320588Phase 1/2
- A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)RecruitingNCT05319730Phase 1/2
- Ivermectin in Combination With Balstilimab or Pembrolizumab in Patients With Metastatic Triple Negative Breast CancerRecruitingNCT05318469Phase 1/2
- Pembrolizumab and Brentuximab Vedotin in Subjects With Relapsed/Refractory T-cell LymphomaRecruitingNCT05313243Phase 2
- A Study of Pembrolizumab (MK-3475) Plus Platinum and Gemcitabine as First Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (PIPER)RecruitingNCT05286619Phase 2
- Efficacy of Platinum-based Chemotherapy Plus Immune Checkpoint Inhibitors for EGFR/ALK/ROS1 Mutant Lung CancerRecruitingNCT05284539Phase 2
- Pembrolizumab Plus Chemo in Neoadjuvant Treatment of Esophageal Squamous Cell Carcinoma (Eastern Cooperative Thoracic Oncology Projects 2004, ECTOP-2004)RecruitingNCT05281003Phase 2
- Evaluation of RBS2418 in Subjects With Advanced, Metastatic Solid TumorsRecruitingNCT05270213Phase 1
- Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid TumorsRecruitingNCT05269381Phase 1/2
- Pembrolizumab Plus Bevacizumab and Chemotherapy for ALK-rearranged NSCLC With Persistent 5'ALKRecruitingNCT05266846Phase 2
- The Assessment of Immune Response in Newly Diagnosed Glioblastoma Patients Treated With PembrolizumabRecruitingNCT05235737Phase 4
- Determine Safety & Recommended Phase 2 Dosing of Zeaxanthin Alone or in Combination w/Pembrolizumab in Patients With Metastatic CancerRecruitingNCT05232409Phase 1
- A Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of ATG 037 Monotherapy and Combination Therapy With Pembrolizumab in Patients With Advanced Solid TumorsRecruitingNCT05205109Phase 1
- Pembrolizumab, Olaparib, and Temozolomide for People With GliomaRecruitingNCT05188508Phase 2
- Triplex Checkpoint Inhibitors Therapy for Advanced Solid TumorsRecruitingNCT05187338Phase 1/2
- Perioperative Pembrolizumab and Lenvatinib in Resectable Hepatocellular Carcinoma (HCC)RecruitingNCT05185739Phase 2
- Pembrolizumab and Brentuximab Vedotin vs GDP and Stem Cell Transplant for Relapsed/Refractory Hodgkin LymphomaRecruitingNCT05180097Phase 2
- Neoadjuvant Folfirinox Combined With Pembrolizumab Followed by Surgery for Patients With Resectable Pancreatic CancerRecruitingNCT05132504Phase 2
- First in Human Study of T3P-Y058-739 (T3P)RecruitingNCT05120596Phase 1/2
- Safety Lead-In Study of a Repurposed Drug Added to the Combination of Len Plus PemNot yet recruitingNCT05106127Phase 2
- Axitinib +/- Pembrolizumab in First Line Treatment of mPRCCRecruitingNCT05096390Phase 2
- Pembrolizumab With Olaparib as Combined Therapy in Metastatic Pancreatic CancerRecruitingNCT05093231Phase 2
- A Randomised Open-label Phase III Trial of REduced Frequency Pembrolizumab immuNothErapy for First-line Treatment of Patients With Advanced Non-small Cell Lung Cancer (NSCLC)RecruitingNCT05085028Phase 3
- Study of Pembrolizumab and M032 (NSC 733972)RecruitingNCT05084430Phase 1/2
- Pembrolizumab Monotherapy Following Tri-modality Treatment for Selected Patients With Muscle-invasive Bladder CancerRecruitingNCT05072600Phase 2
- Phase II Study of Pembrolizumab in Combination With Lenvatinib in Patients With TNBC, NSCLC, and Other Tumor Types and Brain MetastasesRecruitingNCT05064280Phase 2
- Efficacy and Biomarker Development for Lung Cancer Treated With Immune Checkpoint InhibitorsRecruitingNCT05055908Phase 3
- Alpha Radiation Emitters Device (DaRT) in Combination With Check Point Inhibitor for the Treatment of Recurrent Unresectable or mHNSCCRecruitingNCT05047094Not applicable
- A Trial of Camrelizumab Combined With Famitinib Malate in Treatment Naïve Subjects With PD-L1-Positive Recurrent or Metastatic Non-Small Cell Lung CancerRecruitingNCT05042375Phase 3
- Immunotherapy With Chemotherapy and Chemoradiation for Advanced Squamous Cancer of Nasal Cavity / Paranasal Sinuses (I-NAPA)RecruitingNCT05027633Phase 2
- Neoadjuvant Pembrolizumab in Cutaneous Squamous Cell CarcinomaRecruitingNCT05025813Phase 2
- NeoAdjuvant Pembrolizumab and STEreotactic Radiotherapy Prior to Nephrectomy for Renal Cell CarcinomaRecruitingNCT05024318Phase 2
- Correlation of Clinical Response to Pathologic Response in Patients With Early Breast CancerRecruitingNCT05020860Phase 2
- HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced SarcomaRecruitingNCT04995003Phase 1
- Study of Pembrolizumab Treatment After CYAD-101 With FOLFOX Preconditioning in Metastatic Colorectal CancerRecruitingNCT04991948Phase 1
- Study of Palliative Radiation Combined with Pembrolizumab in Unresectable Metastatic Stage IV Breast CancerRecruitingNCT04990921Phase 2
- GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid TumorsRecruitingNCT04977453Phase 1/2
- Trial of Anti-PD-1 Immunotherapy and Stereotactic Radiation in Patients With Recurrent GlioblastomaRecruitingNCT04977375Phase 1/2
- SRT in Combination With Pembrolizumab in Patients With Recurrent Prostate Cancer After Radical ProstatectomyRecruitingNCT04931979Phase 2
- APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant EffusionRecruitingNCT04919629Phase 2
- Dose Tapering and Early Discontinuation to InCreAse cosT-effectIveness Of Immunotherapy for NSCLCRecruitingNCT04909684Phase 3
- Olaptesed With Pembrolizumab and Nanoliposomal Irinotecan or Gemcitabine/Nab-Paclitaxel in MSS Pancreatic CancerNot yet recruitingNCT04901741Phase 2
- A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2RecruitingNCT04879329Phase 2
- Trial Exploring Combined Neoadjuvant Therapy With Pembrolizumab/Lenvatinib + Adjuvant Pembrolizumab in Pat. With NSCLCRecruitingNCT04875585Phase 2
- Pembrolizumab and Lenvatinib in Advanced Cervical CancerRecruitingNCT04865887Phase 2
- Pembrolizumab in Combination With Salvage Chemotherapy for First-relapsed or Refractory Classical Hodgkin LymphomaRecruitingNCT04838652Phase 2
- Pembrolizumab Plus Neoadjuvant Chemotherapy vs. Neoadjuvant Chemoradiotherapy for Locally Advanced ESCC (KEYSTONE-002)RecruitingNCT04807673Phase 3
- Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067RecruitingNCT04787042Phase 1/2
- BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)RecruitingNCT04752826Phase 1/2
- Sacituzumab Govitecan Plus EV in Metastatic UCRecruitingNCT04724018Phase 1/2
- Intralesional Influenza Vaccine for the Treatment of Stage I-IV MelanomaRecruitingNCT04697576Phase 1
- Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell CarcinomaRecruitingNCT04671667Phase 2
- Merck IIT: RRP Pembro and LenvatinibRecruitingNCT04645602Phase 2
- Addition of Pembrolizumab to the Standard of Care Chemotherapy in Patient With SCCOHTRecruitingNCT04602377Phase 2
- Pembrolizumab, Olaparib, Recurrent/Advanced Gastric and Gastro-esophageal Junction(GEJ) CancerRecruitingNCT04592211Phase 1/2
- Imatinib Mesylate in Combination With Pembrolizumab in Patients With MelanomaRecruitingNCT04546074Phase 1/2
- Pembrolizumab and Lenvatinib for Platinum- Sensitive Recurrent Ovarian CancerRecruitingNCT04519151Phase 2
- Study of Pembrolizumab With Bendamustine in Hodgkin LymphomaRecruitingNCT04510636Phase 2
- A Study of Pembrolizumab+ sEphB4 in Metastatic Urothelial CarcinomaRecruitingNCT04486781Phase 2
- Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBCRecruitingNCT04468061Phase 2
- An Open-Label Study of INV-1120 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced Solid TumorsRecruitingNCT04443088Phase 1
- Pembrolizumab, Ibrutinib and Rituximab in PCNSLRecruitingNCT04421560Phase 1/2
- Study on Pembrolizumab in Recurrent, Platinum Resistant, CPS >1 Positive Ovarian, Fallopian Tube and Primary Peritoneal Cancer PatientsRecruitingNCT04375956Phase 2
- A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid TumorsRecruitingNCT04370587Phase 1/2
- Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast CancerRecruitingNCT04348747Phase 2
- A Study of Pembrolizumab Plus Local Chemotherapy Using Isolated Limb Infusion (ILI) for Patients With Sarcoma in the Arm or LegRecruitingNCT04332874Phase 2
- Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal MelanomaRecruitingNCT04318717Phase 2
- Adjuvant Pembrolizumab vs Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cmRecruitingNCT04317534Phase 2
- Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])RecruitingNCT04267848Phase 3
- Chemotherapy and Immunotherapy as Treatment for MSS Metastatic Colorectal Cancer With High Immune InfiltrateRecruitingNCT04262687Phase 2
- Pilot Study of Performance Status 2 vs. Performance Status 0-1 Non-small Cell Lung Cancer Patients Treated With Chemo/ImmunotherapyRecruitingNCT04253964Phase 2
- Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)RecruitingNCT04198766Phase 1/2
- Checkpoint Inhibition In Pediatric Hepatocellular CarcinomaRecruitingNCT04134559Phase 2
- Neo-adjuvant Pembrolizumab and Radiotherapy in Localised MSS Rectal CancerRecruitingNCT04109755Phase 2
- Neoadjuvant Therapy of Pembrolizumab + Ramucirumab for PD-L1 Positive Stage IB-IIIA Lung Cancer (EAST ENERGY)RecruitingNCT04040361Phase 2
- Pembrolizumab and Oral Metronomic Cyclophosphamide in Patients With Chest Wall Breast CancerRecruitingNCT03971045Phase 2
- Pan Tumor Rollover StudyRecruitingNCT03899155Phase 2
- Neoadjuvant Combination Immunotherapy for Stage III MelanomaRecruitingNCT03842943Phase 2
- Evaluating the Safety and Efficacy of Pembrolizumab Combined With MWA for Advanced NSCLCRecruitingNCT03769129Not applicable